NUTRILIPID 10%

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NUTRILIPID 10% (NUTRILIPID 10%).

How it works

Nutrilipid 10% is a fat emulsion that provides essential fatty acids (linoleic and linolenic acids) and a source of calories. It serves as a component of parenteral nutrition, supplying triglycerides that are metabolized to free fatty acids and glycerol for energy production and cellular functions.

What the body does with it

Metabolism	Metabolized by lipoprotein lipase in the capillaries to free fatty acids and glycerol; free fatty acids undergo beta-oxidation in mitochondria for energy or are re-esterified for storage.
Excretion	Renal: negligible; biliary/fecal: not applicable as lipid emulsion is metabolized; elimination primarily via lipoprotein lipase-mediated clearance from plasma.
Half-life	Terminal elimination half-life: approximately 0.5-1 hour for the triglyceride component in healthy adults; clinically, clearance depends on infusion rate and metabolic capacity, with prolonged half-life in hypertriglyceridemia.
Protein binding	Not protein-bound; lipid particles are emulsions; binding to lipoproteins occurs after metabolism.
Volume of Distribution	Vd: approximately 0.1 L/kg (confined to plasma compartment initially); distributes to tissues as chylomicron-like particles.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: immediate (within minutes) as it provides a caloric source upon infusion.
Duration of Action	Duration: 4-6 hours post-infusion for fatty acid oxidation; clinical effect on energy balance persists as long as infusion continues.

Classification & Brands

Dosing & administration

Intravenous infusion, 1-2 g/kg/day (0.5-1 g/kg/day for 10% emulsion), not to exceed 2.5 g/kg/day. Initial rate 0.5-1 mL/min for first 15-30 minutes, then increase to maximum of 125 mL/hour.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR < 30 mL/min/1.73 m²) due to risk of lipid accumulation and electrolyte abnormalities. For moderate impairment (GFR 30-59 mL/min/1.73 m²), reduce dose by 25-50% and monitor serum triglycerides and electrolytes.
Liver impairment	Contraindicated in Child-Pugh class C cirrhosis. For Child-Pugh class B, reduce dose by 50% and monitor triglycerides and liver function. For class A, usual dose with careful monitoring.
Pediatric use	Intravenous infusion, starting at 0.5-1 g/kg/day (5-10 mL/kg/day for 10% emulsion), increase by 0.5 g/kg/day to maximum 2-3 g/kg/day. Monitor triglycerides closely.
Geriatric use	Start at lower end of dosing range (0.5-1 g/kg/day) due to reduced hepatic clearance and altered lipid metabolism. Maximum infusion rate not to exceed 0.1 g/kg/hour. Monitor serum triglycerides and fluid status.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NUTRILIPID 10% (NUTRILIPID 10%).

Breastfeeding	Not excreted into breast milk in significant amounts; lipids are normal constituents. M/P ratio not available. Considered compatible with breastfeeding.
Teratogenic Risk	Intravenous fat emulsions are not teratogenic in animal studies. There are no adequate human data. Use only if clearly needed. First trimester: theoretical risk from essential fatty acid deficiency if withheld. Second and third trimesters: risk of maternal hypertriglyceridemia and pancreatitis, which may indirectly affect fetus. No known direct fetal toxicity.

Warnings & precautions

■ FDA Black Box Warning

Death in preterm infants has been reported with intravenous fat emulsion products. Preterm infants have poor ability to clear intravenous lipids; careful monitoring of serum triglycerides and other lipids is necessary.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe hyperlipidemia","Severe coagulopathy","Egg or soybean allergy (contraindicated in patients with known hypersensitivity to egg or soybean proteins)","Unstable or severe metabolic acidosis"]

Clinical Precautions

Precautions

["Risk of hypertriglyceridemia; monitor serum triglycerides regularly","Risk of fat overload syndrome (hepatomegaly, splenomegaly, thrombocytopenia, coagulopathy, hyperlipidemia) with prolonged use or excessive doses","Monitor for signs of infection; aseptic technique required due to risk of contamination","Use with caution in patients with severe liver disease, coagulopathy, or hyperlipidemia"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NUTRILIPID 10%

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NUTRILIPID 10% (NUTRILIPID 10%).

How it works

What the body does with it

Metabolism	Metabolized by lipoprotein lipase in the capillaries to free fatty acids and glycerol; free fatty acids undergo beta-oxidation in mitochondria for energy or are re-esterified for storage.
Excretion	Renal: negligible; biliary/fecal: not applicable as lipid emulsion is metabolized; elimination primarily via lipoprotein lipase-mediated clearance from plasma.
Half-life	Terminal elimination half-life: approximately 0.5-1 hour for the triglyceride component in healthy adults; clinically, clearance depends on infusion rate and metabolic capacity, with prolonged half-life in hypertriglyceridemia.
Protein binding	Not protein-bound; lipid particles are emulsions; binding to lipoproteins occurs after metabolism.
Volume of Distribution	Vd: approximately 0.1 L/kg (confined to plasma compartment initially); distributes to tissues as chylomicron-like particles.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: immediate (within minutes) as it provides a caloric source upon infusion.
Duration of Action	Duration: 4-6 hours post-infusion for fatty acid oxidation; clinical effect on energy balance persists as long as infusion continues.

Classification & Brands

Dosing & administration

Intravenous infusion, 1-2 g/kg/day (0.5-1 g/kg/day for 10% emulsion), not to exceed 2.5 g/kg/day. Initial rate 0.5-1 mL/min for first 15-30 minutes, then increase to maximum of 125 mL/hour.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR < 30 mL/min/1.73 m²) due to risk of lipid accumulation and electrolyte abnormalities. For moderate impairment (GFR 30-59 mL/min/1.73 m²), reduce dose by 25-50% and monitor serum triglycerides and electrolytes.
Liver impairment	Contraindicated in Child-Pugh class C cirrhosis. For Child-Pugh class B, reduce dose by 50% and monitor triglycerides and liver function. For class A, usual dose with careful monitoring.
Pediatric use	Intravenous infusion, starting at 0.5-1 g/kg/day (5-10 mL/kg/day for 10% emulsion), increase by 0.5 g/kg/day to maximum 2-3 g/kg/day. Monitor triglycerides closely.
Geriatric use	Start at lower end of dosing range (0.5-1 g/kg/day) due to reduced hepatic clearance and altered lipid metabolism. Maximum infusion rate not to exceed 0.1 g/kg/hour. Monitor serum triglycerides and fluid status.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NUTRILIPID 10% (NUTRILIPID 10%).

Breastfeeding	Not excreted into breast milk in significant amounts; lipids are normal constituents. M/P ratio not available. Considered compatible with breastfeeding.
Teratogenic Risk	Intravenous fat emulsions are not teratogenic in animal studies. There are no adequate human data. Use only if clearly needed. First trimester: theoretical risk from essential fatty acid deficiency if withheld. Second and third trimesters: risk of maternal hypertriglyceridemia and pancreatitis, which may indirectly affect fetus. No known direct fetal toxicity.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe hyperlipidemia","Severe coagulopathy","Egg or soybean allergy (contraindicated in patients with known hypersensitivity to egg or soybean proteins)","Unstable or severe metabolic acidosis"]